Anti-Angiogenesis Strategies in Cancer Therapies

Anti-Angiogenesis Strategies in Cancer Therapies

By (author)  , By (author) 

Free delivery worldwide

Available. Dispatched from the UK in 2 business days
When will my order arrive?


Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.

Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
show more

Product details

  • Paperback | 210 pages
  • 191 x 235 x 12.7mm | 340g
  • Academic Press Inc
  • San Diego, United States
  • English
  • 012802576X
  • 9780128025765
  • 1,251,973

Table of contents

1. Role of Angiogenesis and lymphogenesis in Cancer (tumor growth, Invasion, metastasis 2. Role of Angiogenesis and anti-angiogenesis in hematological malignancies (acute / chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms) 3. The interface between Thrombosis-Inflammation and Angiogenesis 4. Micro RNA and Angiogenesis modulation 5. Preclinical discovery and development of different Pharmacological anti-angiogenesis agents 6. Differences among different anti-angiogenesis strategies (Mechanisms of actions) 7. Naturally Occurring Anti-angiogenesis 8. Clinical trials with anti-angiogenesis agents: Approved agents 9. Angiogenesis Biomarkers and Impact on personalized management 10. Efficacy of Anti-VEGF therapy in cancer 11. Nanotechnology in enhancing the utility of anti-angiogenesis agents - Combinations with other anti-cancer agents 12. Multi-targeted anti-angiogenesis therapy in cancer 13. Combination of anti-angiogenesis and chemotherapeutics 14. Nanotechnology in enhancing the utility of anti-angiogenesis agents - Combinations with other anti-cancer agents 15. Nano-targeted anti-angiogenesis agents in cancer detection 16. Future Directions
show more

Review quote

"...a comprehensive overview of all aspects of angiogenesis. The assessment of FDA-approved antiangiogenesis agents in cancer therapy and new applications of nanotechnology in antiangiogenesis interventions are very valuable to the field. Score: 98 - 5 Stars!" --Doody's
show more

About Shaker A. Mousa

Dr. Mousa came to Albany College of Pharmacy and Health Sciences in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. Among Dr. Mousa's professional accomplishments are his contributions to many patents - he holds more than 250 U.S. and international patents - and to the discovery and development of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial perfusion and thrombus imaging agents. Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Journal of Pharmaceutical Sciences, Frontiers in Molecular Neuroscience, Clinical and Applied Thrombosis/Hemostasis, Applied Microbiology and Biotechnology, and PLoS Computational Biology. Dr. Davis directs a group of scientists who have defined molecular mechanisms for many non-genomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. He has 5 patents issued and 25 US and international applications pending. Dr. Davis is a US Faculty Head in Endocrinology of the Faculty of 1000 Medicine and a member of the Endocrine Society, American Thyroid Association, American Society of Biochemistry and Molecular Biology, American Diabetes Association, American Association for Cancer Research and a Fellow of the American College of Physicians.
show more